Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14026 - 14050 of 14501 in total

Picloxydine

Experimental

Sulbentine

Experimental

Xibornol

Experimental

Guanoclor

Experimental

Clofibride

Experimental

Bisoxatin acetate

Experimental

Motexafin lutetium

Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational

DERIVATIVE OF AKLANONIC ACID METHYL ESTER (AAME)

Experimental

Talviraline

Talviraline has been used in trials studying the treatment of HIV Infections.
Investigational

4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL

Experimental

3-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME

Experimental

Dexetimide

A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn

Piclozotan

Piclozotan has been investigated for the treatment of Parkinson's Disease.
Investigational

Mephenoxalone

Experimental

Rose bengal lactone

Experimental

Candoxatril

Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.
Experimental

A-98881

Experimental

6-(2-Oxo-Hexahydro-Thieno[3,4-D]Imidazol-4-Yl)-Hexanoic Acid

Experimental

N-[Tosyl-D-Prolinyl]Amino-Ethanethiol

Experimental

(7R)-7-(6,7-Dihydro-5H-cyclopenta[d]imidazo[2,1-b][1,3]thiazol-2-yl)-2,7-dihydro-1,4-thiazepine-3,6-dicarboxylic acid

Experimental

(2R)-2-{(1R)-2-oxo-1-[(2-thienylacetyl)amino]ethyl}-5,6-dihydro-2h-1,3-thiazine-4-carboxylic acid

Experimental

4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL

Experimental

(5S)-2-{[(1S)-1-(4-Fluorophenyl)ethyl]amino}-5-(2-hydroxy-2-propanyl)-5-methyl-1,3-thiazol-4(5H)-one

Experimental

BMS-564929

BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental

CCT-018159

Experimental
Displaying drugs 14026 - 14050 of 14501 in total